Zobrazeno 1 - 10 of 197 pro vyhledávání: '"Michel M Van Den Heuvel"'
1
Akademický článek
Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer.
Autor: Karlijn Hummelink, Vincent van der Noort, Mirte Muller, Robert D Schouten, Michel M van den Heuvel, Daniela S Thommen, Egbert F Smit, Gerrit A Meijer, Kim Monkhorst
Publikováno v: PLoS ONE, Vol 19, Iss 7, p e0293707 (2024)
BackgroundThe efficacy of PD-1 blocking agents in advanced NSCLC has shown prolonged effectiveness, but only in a minority of patients. Multiple biomarkers have been explored to predict treatment benefit, yet their combined performance remains inadeq
Externí odkaz: https://doaj.org/article/6b18e0bcb87f45658fff43824048aa27
Zobrazit plný text záznamu
2
Akademický článek
Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination
Autor: Kim Monkhorst, Johannes Textor, Michel M van den Heuvel, Katrien Grünberg, Jeroen H A Creemers, Carl G Figdor, I Jolanda M de Vries, Lieke L van der Woude, Mark A J Gorris, Inge M N Wortel, Kiek Verrijp, Berber Piet, Willemijn S M E Theelen
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 10, Iss 10 (2022)
Background Immunotherapy is currently part of the standard of care for patients with advanced-stage non-small cell lung cancer (NSCLC). However, many patients do not respond to this treatment, therefore combination strategies are being explored to in
Externí odkaz: https://doaj.org/article/663cd6a76af94357ad61372c788c6ddb
Zobrazit plný text záznamu
3
Akademický článek
A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test
Autor: Thomas Muley, Xiaotong Zhang, Stefan Holdenrieder, Catharina M Korse, Xiu-yi Zhi, Rafael Molina, Zhongjuan Liu, Gunther Hartmann, Michel M van den Heuvel, Kun Qian, Ramon Marrades, Christine Engel, Ying He, Birgit Wehnl, Farshid Dayyani, Felix Herth
Publikováno v: Tumor Biology, Vol 42 (2020)
This study aimed to investigate whether changes in progastrin-releasing peptide (ProGRP) levels correlate with treatment response and can be used to optimize clinical management of patients with small-cell lung cancer. Patients with small-cell lung c
Externí odkaz: https://doaj.org/article/de453d033ca24de7ad50985f43964c44
Zobrazit plný text záznamu
4
Akademický článek
Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer.
Autor: Willemijn S M E Theelen, Thomas Kuilman, Katja Schulze, Wei Zou, Oscar Krijgsman, Dennis D G C Peters, Sten Cornelissen, Kim Monkhorst, Pranamee Sarma, Teiko Sumiyoshi, Lukas C Amler, Stefan M Willems, Johannes L G Blaauwgeers, Carel J M van Noesel, Daniel S Peeper, Michel M van den Heuvel, Marcin Kowanetz
Publikováno v: PLoS ONE, Vol 14, Iss 5, p e0216864 (2019)
BackgroundIn non-small cell lung cancer (NSCLC), PD-L1 expression on either tumor cells (TC) or both TC and tumor-infiltrating immune cells (IC) is currently the most used biomarker in cancer immunotherapy. However, the mechanisms involved in PD-L1 r
Externí odkaz: https://doaj.org/article/71ec07804c5045b0afac420650e42855
Zobrazit plný text záznamu
5
Akademický článek
Modeling strategies to analyse longitudinal biomarker data: An illustration on predicting immunotherapy non-response in non-small cell lung cancer
Autor: Frederik A. van Delft, Milou Schuurbiers, Mirte Muller, Sjaak A. Burgers, Huub H. van Rossum, Maarten J. IJzerman, Hendrik Koffijberg, Michel M. van den Heuvel
Publikováno v: Heliyon, Vol 8, Iss 10, Pp e10932- (2022)
Serum tumor markers acquired through a blood draw are known to reflect tumor activity. Their non-invasive nature allows for more frequent testing compared to traditional imaging methods used for response evaluations. Our study aims to compare nine pr
Externí odkaz: https://doaj.org/article/457e2192e21a4b678c80294951df3697
Zobrazit plný text záznamu
6
Akademický článek
Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer
Autor: Leila S. Otten, Berber Piet, Michel M. van den Heuvel, Catia Marzolini, Robin M.J.M. van Geel, Judith L. Gulikers, David M. Burger, Jenneke Leentjens, Rob ter Heine
Publikováno v: European Respiratory Review, Vol 31, Iss 164 (2022)
Background The risk for thromboembolisms in nonsmall cell lung cancer (NSCLC) patients is increased and often requires treatment or prophylaxis with direct oral anticoagulants (DOACs). Small-molecule inhibitors (SMIs) to treat NSCLC may cause relevan
Externí odkaz: https://doaj.org/article/021ff43369ae431abd9f0b019aca1b8f
Zobrazit plný text záznamu
7
Clinical perspectives on serum tumor marker use in predicting prognosis and treatment response in advanced non-small cell lung cancer
Autor: Alessandra I.G. Buma, Milou M.F. Schuurbiers, Huub H. van Rossum, Michel M. van den Heuvel
Publikováno v: Tumor Biology. :1-11
The optimal positioning and usage of serum tumor markers (STMs) in advanced non-small cell lung cancer (NSCLC) care is still unclear. This review aimed to provide an overview of the potential use and value of STMs in routine advanced NSCLC care for t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cfe1b393e54326b8b1fe2e75bce68190
https://doi.org/10.3233/tub-220034
Zobrazit plný text záznamu
9
Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial
Autor: Nikki de Rouw, René J. Boosman, Jacobus A. Burgers, Alwin D. R. Huitema, Anne-Marie C. Dingemans, Hieronymus. J. Derijks, David M. Burger, Berber Piet, Lizza E. L. Hendriks, Bonne Biesma, Melinda A. Pruis, Daphne W. Dumoulin, Sander Croes, Ron H. J. Mathijssen, Michel M. van den Heuvel, Rob ter Heine
Publikováno v: Cancer Chemotherapy and Pharmacology, 91, 33-42
Cancer Chemotherapy and Pharmacology, 91(1), 33-42. Springer Verlag
Cancer Chemotherapy and Pharmacology, 91(1), 33-42. Springer-Verlag
Cancer Chemotherapy and Pharmacology, 91, 1, pp. 33-42
Item does not contain fulltext PURPOSE: Pemetrexed is a chemotherapeutic drug in the treatment of non-small cell lung cancer and mesothelioma. Optimized dosing of pemetrexed based on renal function instead of body surface area (BSA) is hypothesized t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f89d8fdab2aea47b4e702192ee6d7831
https://hdl.handle.net/2066/290955
Zobrazit plný text záznamu
10
Akademický článek
Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing Complexity
Autor: Daan van den Broek, T. Jeroen N. Hiltermann, Bonne Biesma, Winand N. M. Dinjens, Nils A. 't Hart, John W. J. Hinrichs, Mathie P. G. Leers, Kim Monkhorst, Matthijs van Oosterhout, Volkher Scharnhorst, Ed Schuuring, Ernst-Jan M. Speel, Michel M. van den Heuvel, Ron H. N. van Schaik, Jan von der Thüsen, Stefan M. Willems, Leonie de Visser, Marjolijn J. L. Ligtenberg
Publikováno v: Frontiers in Oncology, Vol 9 (2020)
The diagnostic landscape of non-small cell lung cancer (NSCLC) is changing rapidly with the availability of novel treatments. Despite high-level healthcare in the Netherlands, not all patients with NSCLC are tested with the currently relevant predict
Externí odkaz: https://doaj.org/article/690a5016a3c44acc879bb9a893ae5eb8
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje